Comparison of Antibiotic Sensitivity of Pattern Candida albicans and Candida parapsilosis Isolated From Clinical Samples In Intensive Care Unit
A retrospective analysis of the widely used antibiotics all susceptibility testing results from Candida (C.) albicans and Candida (C.) parapsilosis cultured from clinical specimens private hospital (2014-2018) was performed. The VITEK 2 Compact automated microbiology system (bioMérieux) is designed for automated rapid antimicrobial susceptibility testing and identification of clinically relevant Candida isolates. Minimum Inhibitory Concentration (MIC) results previously obtained in recent clinical isolates with well-defined in isolates with well-characterized resistance mechanisms with the microdilution method were re-interpreted for the susceptible, intermediate and resistant categories using the 2018 EUCAST breakpoints. Clinical samples are most commonly isolated from blood, wound and urine samples. In our study, Vorikanozol and Flucytosine showed 100% sensitivity rate both C. albicans and C. parapsilosis. MAR index value showed only one sample, 0.33 both C.albicans and C.parapsilosis. Considering the antibiogram, Vorikanozol and Flucytosine should be preferred drugs for both C.albicans and C.parapsilosis infection isolated from clinical samples
C.albicans, C.parapsilosis, antibiotic, sensitivity, clinical specimens, intensive care unit
i. Brown, G. D. and Netea, M. G. 2007. Immunology of Fungal Infections. Dordrecht Springer.
ii. Marodi, L. and Johnston, R. B. Jr. 2007. Invasive Candida species disease in infants and children: occurrence, risk factors, management, and innate host defense mechanisms, Curr Opin Pediatr 19: 693-697.
iii. Neofytos, D., Fishman, J. A. and Horn, D. 2010. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients, Transpl Infect Dis, 12: 220-229.
iv. Pfaller, M. A. and Diekema, D. J. 2010. Epidemiology of invasive mycoses in North America, Crit Rev Microbiol 36: 1-53.
v. Trick, W.E., Fridkin, S.K., Edwards, J.R., Hajjeh, R.A. and Gaynes, R.P. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999, Clin Infect Dis, 35:627-630.
vi. Wingard, J.R., Merz, W. G. and Rinaldi, M. G. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole, N Engl J Med 325: 1274-1277.
vii. Clark, T. A., Slavinski, S. A., Morgan, J., Lott, T., Arthington-Skaggs, B. A. and Brandt, M. E. 2004. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 42:4468-72.
viii. Almirante, B., Rodriguez, D., Cuenca-Estrella, M., Almela, M., Sanchez, F. and Ayats, J. 2006. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 44: 1681-1685.
ix. Cappuccino, J.G. and N. Sherman. 2004. Microbiology: A Laboratory Manual. 7th Edn., Pearson Education (Singapore), Indian Branch, New Delhi, ISBN: 080532836X pp: 544.
x. Gunasekaran, P. 2000. Laboratory Manual in Microbiology. New Age. International, New Delhi.
xi. MacFaddin, F.J. 2000. Biochemical Tests for Identification of Medical Bacteria., 3rd Edn., Philadelphia, USA, p.912.
xii. Pfaller, M.A., Houston, A. and Coffmann, S. 1996. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei and Candida (Torulopsis) glabrata. J. Clin. Microbiol. 34: 58-61.
xiii. Krumperman, P. H. 1985. Multiple antibiotic resistance indexing of Escherichia coli to identify high-risk sources of fecal contamination of foods. Applied and Environmental. Microbiology, 46:165– 170.
xiv. Matyar, F., Kaya, A. and Dinçer, S. 2008. Antibacterial agents and heavy metal resistance in Gram-negative bacteria isolated from seawater, shrimp, and sediment in Iskenderun Bay, Turkey. Science Total and Environment, 407: 279-285.
xv. Badiee, P. and Alborzi, A. 2011. Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study. Iran. J. Microbiol., 3 (4): 183-188.
xvi. Adilo?lu, A. K., ?irin, M. C., Cicioglu-Ar?do?an, B., Can, R. and Demirci, M. 2004. Çe?itli klinik örneklerden izole edilen Candida kökenlerinin identifikasyonu ve antifungal duyarl?l?klar?n?n ara?t?r?lmas?. ADÜ T?p Fak Derg, 5(3):33-36.
xvii. Pfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J. and Diekema, D. J. 2002. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46(11):3518-3521.
xviii. Altanlar, N., Erdemo?lu, A., Emekda?, G., Kocabeyo?lu, Ö. and Ak?n, A. 1999. De?i?ik klinik örneklerden izole edilen Candida türlerinin da??l?m? ve antifungal duyarl?l?klar?n?n ara?t?r?lmas?. ANKEM Derg. 13(1):92-96.
xix. Ç?kman, A., Parlak, M., Ceylan, M. R., Güdücüo?lu, H. and Berkta?, M. 2014. Çe?itli Klinik Örneklerden Soyutlanan Kandidalar?n Tür Da??l?m? ve Antifungal Direnci. Van T?p Dergisi, 21(1):1-5.
xx. Emri, T., Majoros, L., Toth, V. and Pocsi, I. 2013. Echinocandins: production and applications. Appl Microbiol Biotechnol. 97:3267–3284.
xxi. Quindós, G., Eraso, E., Javier Carrillo-Munoz, A., Cantón, E. and Pemán, J. 2009. In vitro antifungal activity of micafungin. Rev Iberoam Micol. 26: 35–41.
xxii. Vijgen, S., Nys, S., Naesens, R., Magerman, K., Boel, A. and Cartuyvels, R. 2011. Comparison of Vitek identification and antifungal susceptibility testing methods to DNA sequencing and Sensititre YeastOne antifungal testing. Med Mycol. 49(1):107–110.Cite this Article: